Lastly, a phase I trial that is currently recruiting will attempt to evaluate the combination of ZEN003694, a BET inhibitor (BETi), with the HDAC entinostat in patients with hematologic malignancies, as well as those with solid tumors overexpressing BET (NCT05053971). Here, HDAC9 is linked to hematologic disorder.